Integrated Drug Discovery
Offering End-to-End Solutions
IND-Enabling Projects
Axcelead acquired multiple projects from Takeda through its spin-out in 2017 in multiple therapeutic areas including Oncology, Inflammation and Immunology, Metabolic Disorders and neuroscience. These exciting projects are available for co-creation of drug candidates with our customers. The IND-Enabling Projects provide an opportunity for newly generated IP, which is owned by our customers. To help you advance an IND-Enabling Projects, Axcelead drug discovery services are capable of advancing projects to IND filing and beyond.
Currently, we have over 150 small molecule and peptide projects against the select below high-value therapeutic targets:
- ERBB4 inhibitor
- IAP antagonist
- MAPK14 inhibitor
- HCN4 inhibitor
If you are interested in learning more, please reach out directly to our business development department.